References
- Van der Oever R, Hepp B, Debbaut B, Simon I. Socioeconomic impact of chronic venous insufficiency. An underestimated public health problem. Int Angiol 1998;17:161–7
- Sailer M, Bussen D, Debris ES. Quality of life in patients with benign anorectal disorders. Br J Surg 1998;85:1716–9
- Ahmed SK, Thompson HJ. The effect of breakfast on minor anal complaints: A matched case-control study. J Roy Coll Surg Edin 1997;42:331–3
- Cheatle TR, Scurr JH, Coleridge Smith PD. Drug treatment of chronic venous insufficiency and venous ulceration: A review. J Roy Soc Med 1991;84:354–8
- Wadworth AN, Faulds D. Hydroxyethylrutosides. A review of its pharmacology and therapeutic efficacy in venous insufficiency and related disorders. Drugs 1992;44:1013–32
- Wenisch C, Biffignandi PM. Effect of bioflavonoids (trihydroxyethylrutin and disodium flavodate) in vitro on neutrophil reactive oxygen production and phagocytic ability assessed by flow cytometry. Curr Med Res Opin 2001;17(2):123–7
- Radtke H, Kiesewettrer H, Schneider R. Die rheologische Wirksamkeit von cumarin und troxerutin. Therapiewoche 1983;49:6662–6
- Boada JN, Nazco GJ. Therapeutic effect of venotonics in chronic venous insufficiency. A meta-analysis. Clin Drug Invest 1999;18:413–32
- MacLennan WJ, Wilson J, Rattenhuber V. Hydroxyethylrutosides in elderly patients with chronic venous insufficiency: its efficacy and tolerability. Gerontology 1994;40:45–52
- Sohn C, Jahnichen C, Bastert G. Effectiveness of bhydroxyethylrutoside in patients with varicose veins in pregnancy. Zentralbl Gynakol 1995;117:190–97
- Frick RW. Three treatments for chronic venous insufficiency: escin, hydroxyethylrutoside, and Daflon. Angiology 2000;51:197–205
- Carlsson K, Patwardhan A, Poullain JC, Gerentes I. Transport et fixation de la troxerutine dans la paroi veineuse. J Mal Vasc 1996;21(Suppl C):270–74
- Krupinski K, Giedrojc J, Bielawiee M. Effect of troxerutin on laser-induced thrombus formation in rat mesenteric vessels, coagulation parameters and platelet function. Pol J Pharmacol 1996;48:335–9
- Boisseau MR, Taccoen A, Garreau C, Vergnes C, Roudaut MF, Garreau-Gomez B. Fibrinolysis and hemorheology in chronic venous insufficiency: a double blind study of troxerutin efficiency. J Cardiovasc Surg 1995;36:369–74
- Squadrito F, Altavilla D, Oliaro Bosso S. Double-blind, randomised clinical trial of Fleboside® in patients with hemorrhoids. Eur Rev Med Pharmacol Sci 2000;4:21–4
- Roland IH, Bougelet C, Ninane N, Arnould T, Michiels C, Remacle J. Effects of hydroxyethylrutosides on hypoxial-induced neutrophil adherence to umbilical vein endothelium. Cardiovasc Drugs Ther 1998;12:375–81
- van Acker FAA, van Acker SABE, Kramer K, Haenen GRMM, Bast A, van der Vijgh WJF. 7-Monohydroxyethylrutoside protects against chronic doxorubicin-induced cardiotoxicity when administered orally once per week. Clin Cancer Res 2000;6:1337–41